Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

Yuhui Huang, Shom Goel, Dan G. Duda, Dai Fukumura, and Rakesh K. Jain

Abstract

The recent approval of Provenge has brought new hope for anticancer vaccine therapies. However, the immunosuppressive tumor microenvironment seems to impair the efficacy of vaccine therapies. The abnormal tumor vasculature creates a hypoxic microenvironment that polarizes inflammatory cells toward immune suppression. Moreover, tumors systemically alter immune cells' proliferation, differentiation, and function via secretion of growth factors and cytokines. For example, VEGF, a major proangiogenic cytokine induced by hypoxia, plays a critical role in immunosuppression via these mechanisms. Hence, antiangiogenic treatment may be an effective modality to potentiate immunotherapy. Here, we discuss the local and systemic effects of VEGF on tumor immunity and propose a potentially translatable strategy to re-engineer the tumor–immune microenvironment and improve cancer immunotherapy by using lower "vascular normalizing" doses of antiangiogenic agents. Cancer Res; 73(10); 2943–8. ©2013 AACR.

Introduction

It is now widely accepted that tumors can be immunogenic. Therefore, active cancer immunotherapies, designed to harness the power of the immune system to selectively eliminate malignant cells while sparing normal tissues, have recently re-entered the limelight (1, 2). In 2010, the U.S. Food and Drug Administration approved the first therapeutic cancer vaccine for clinical use [Provenge (Dendreon); ref. 3], and, presently, more than a dozen of other cancer vaccines are being evaluated in randomized phase II or III clinical trials (1). Despite this renewed hope for cancer immunotherapies, survival benefits from vaccination alone remain modest. Indeed, anticancer vaccines face many challenges, a critical one being the immunosuppressive tumor microenvironment (1, 2, 4, 5). As such, the judicious combination of an immunotherapy with an agent that reprograms the tumor microenvironment is an attractive therapeutic strategy. A growing body of evidence indicates that antiangiogenic agents can normalize the abnormal tumor vasculature and potentially re-engineer the tumor immune microenvironment toward a more immunosupportive environment (5–8). In this minireview, we discuss the interplay among proangiogenic molecules, tumor vessels, and the host immune system and how vessel-targeted therapies may improve the efficacy of anticancer immunotherapy.

The abnormal tumor vasculature creates an immunosuppressive microenvironment

Unlike the vessels of normal tissue, tumor blood vessels are highly abnormal. Driven by the relentless production of proangiogenic factors such as VEGF, tumor angiogenesis proceeds in a dysregulated fashion. As a result, tumor vessels show structural abnormalities including a heterogeneous distribution, tortuosity, dilation, and inadequate perivascular cell (PVC) investment. Functionally, blood flow is at times insufficient and vessels are hyperpermeable. The resultant microenvironment is characterized by patchy hypoperfusion, hypoxia, acidity, and a high interstitial fluid pressure (5, 6, 9). These microenvironmental abnormalities may affect immune cell proliferation, infiltration, survival, and function. Indeed, both preclinical and clinical reports found relative absence of antitumor lymphocytes but detected abundant regulatory immune cells such as tumor-associated macrophages (TAM) and regulatory T cells (Treg; refs. 4, 8, 10–13).

Even though all types of immune cells could infiltrate into tumor parenchyma through functional tumor vessels, suppressive immune cell populations seem to accumulate preferentially in tumors for a number of reasons. First, tumors often express high levels of growth factors, such as colony-stimulating factor (CSF)-I and chemokine (C-C motif) ligand (CCL)-2, which attract monocytes into tumor parenchyma where they differentiate into macrophages (12). Second, the tissue-resident macrophages are known to migrate into hypoxic and necrotic tumor areas where they are converted to TAM phenotype. Third, Treg cells, an immunosuppressive lymphoid cell population, may be preferentially recruited into tumors via upregulation of chemotactic factors, such as CCL-22 (10) and CCL-28 induced by tumor hypoxia (14). Finally, hypoxia and immunosuppressive factors in the tumor microenvironment can polarize TAMs to immunosuppressive phenotype...
impeding the recruitment and activation of effector lymphocytes (8, 10, 15, 16). TAMs have at least 2 phenotypes: M1 and M2. M1-like TAMs can destroy tumor cells through the induction of T-helper (Th) 1 cytokines, such as IFN-γ and interleukin (IL)-12, and stimulation of cytotoxic T lymphocyte immunity. Conversely, M2-like TAMs express high level of arginase (Arg1), IL-10, VEGF, and TGF-β, which suppress Th1 T-cell immunity (10, 17). In cancer, the M2-like TAM phenotype predominates (17), in keeping with the "protumor" immune environment. This is partly due to tumor hypoxia, a direct consequence of the abnormal tumor vasculature. Hypoxia promotes the polarization or differentiation of tumor-infiltrating myeloid cells to M2-like TAMs with high expression levels of IL-10 and Arg1 (16). Indeed, more M2-like TAMs are predominantly located in hypoxic tumor areas, and these cells have proangiogenic effects (15). Furthermore, TAMs in perfused regions of tumors express lower levels of M2-like genes, including Arg1, CSF-1, TGF-β, and matrix metalloproteinase (MMP)-9, than TAMs distant from functional blood vessels (8). These findings suggest the critical role of abnormal tumor vasculature and resulting hypoxia in polarizing TAMs to M2-like phenotype and forming an immunosuppressive tumor microenvironment.

Besides affecting TAM phenotype, hypoxia has more far-reaching consequences on the tumor immune environment. For example, hypoxia alters various metabolic pathways in cancer cells leading to accumulation of immunosuppressive metabolites such as adenosine (18). Hypoxia could also directly suppress T-effector cell function (19).

Thus, the excessive production of proangiogenic factors creates locally an abnormal tumor microenvironment that leads to the preferential accumulation of immune suppressor cells in the tumors.

**Circulating VEGF alters host immune cell proliferation, differentiation, and function**

In cancer, VEGF is present at high levels not just in the tumor but also in the systemic circulation. In addition to its ability to promote an immunosuppressive local tumor microenvironment, VEGF also exerts a systemic influence on immune cell development and function. Dendritic cells (DC) are potent antigen-presenting cells (APC) with a specialized ability to take up antigens and present them to T cells. Elevated levels of circulating VEGF suppress the maturation of DC precursors, promote the proliferation of Tregs, and thus inhibit T-cell immune responses (13, 20, 21). Furthermore, treating mice with recombinant VEGF at concentrations similar to those observed in patients with advanced-stage cancer induces T-cell defects via inhibition of Delta ligand signaling through Notch (22). Finally, the accumulation of myeloid-derived suppressor cells (MDSC) in peripheral immune organs has been observed in both patients with cancer and tumor-bearing animals, and excess VEGF is one causative factor (21, 23). These MDSCs can suppress both T-cell and DC function through a variety of mechanisms (23). Importantly, this systemic immunosuppression induced by excess VEGF can be reversed by the blockade of VEGF/VEGFR2 signaling pathway (13, 21, 24). Thus, elevated levels of systemic VEGF in tumor-bearing hosts play a key role in interfering with the recognition and destruction of tumor cells by the host immune system.

**Combining anti-VEGF therapy with immunotherapy: rationale and current progress**

Given that VEGF can interfere with antitumor immunity both systemically and through the generation of an abnormal local microenvironment, recent efforts have been inspired by the idea that anti-VEGF therapy could facilitate antitumor immunity, offering synergistic benefits when combined with immunotherapy.

Our laboratory has carried out extensive research into the effects of anti-VEGF therapy upon the tumor microenvironment. In both preclinical models and patients, blockade of VEGF can reverse many of the structural and functional abnormalities seen in tumor vessels—a process we have termed "vascular normalization" (5, 6). In short, judicious anti-VEGF therapy can improve tumor vessel perfusion, reduce tumor hypoxia, and, in turn, can enhance the delivery of systemically administered cytotoxic therapy and improve tumor radiosensitivity (5, 6). Targeting other proangiogenic factors, such as platelet-derived growth factor (PDGF), angiopoietins (Ang), and placenta growth factor (PIGF), as well as their cognate receptors and integrins, with antibodies or small-molecule inhibitors may also achieve vascular normalization (reviewed in ref. 6). A recent clinical study showed that an increase in tumor perfusion and oxygenation after antiangiogenic treatment with cediranib in glioblastoma was associated with prolonged overall survival (9, 25). It is conceivable that this improved vessel function could enhance the delivery of immune effector cells into tumors and that a reduction in hypoxia could reprogram immune suppressors in the local microenvironment. Together with the neutralization of the systemic immunosuppressive activity of VEGF, the prospect of combined VEGF blockade and immunotherapy holds great promise and is supported by growing body of evidence as discussed below (8, 24, 26, 27).

**I. Genetically induced vascular normalization can improve antitumor immunity.** Recently published animal studies using elegant genetic models have illustrated how normalization of the tumor vasculature can improve antitumor immunity. In a spontaneous pancreatic insulinoma mouse model (RIP1-Tag5/RGS5<sup>−/−</sup>, RGS5<sup>−/−</sup>) deficiency normalized tumor vessels, resulting in increased PVC coverage and perfusion and leading to increased delivery of adoptively transferred T cells and improved mouse survival (7). In a second study, overexpression of the histidine-rich glycoprotein (HRG) induced a normalized vessel phenotype in solid tumors (through a PIGF-dependent mechanism), evidenced by increased PVC coverage, greater blood perfusion, and reduced hypoxia. In keeping with this phenotype, HRG overexpression augmented DCs and CD8<sup>+</sup> T-cell tumor infiltration and polarized TAMs away from an M2-like phenotype (28). Together, these findings show a mechanistic link between vessel normalization and enhanced immune cell infiltration and function.
II. Pharmacologically induced vascular normalization can improve antitumor immunity. Antiangiogenic drugs have been incorporated as the clinical standard of care for several malignancies (29). A number of studies have examined the benefits of combining antiangiogenic treatment with immunotherapy in several cancer models (Table 1). Combination of anti-VEGF agents with immunotherapies has been successful against highly immunogenic tumors (26, 27), but has shown little or no benefit against immunotolerant neoplasms (27). This may be owing to the high dose of antiangiogenic agents often used in animal models (26, 27), which can lead to shorter time windows of normalization due to rapid and excessive pruning of tumor vessels and resulting hypoxia (5, 6). This may further restrict the access of effector T cells into tumor parenchyma, enhance the immunosuppressive tumor microenvironment, and thus compromise the efficacy of an anticancer immunotherapy.

Table 1. Benefits of combined antiangiogenic and active immune therapies

<table>
<thead>
<tr>
<th>Antiangiogenic strategy</th>
<th>Immunotherapy</th>
<th>Tumor model</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-mouse VEGF mAb</td>
<td>Peptide-pulsed DCs</td>
<td>Sarcoma</td>
<td>↑The number and function of DCs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Tumor growth delay (24).</td>
</tr>
<tr>
<td>Anti-VEGFR2 mAb</td>
<td>GM-CSF secreting, neu-specific whole tumor cell vaccine</td>
<td>Neu-expressing breast carcinoma</td>
<td>↑Infiltration of CD8⁺ T cell.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Tumor regression (in FVB mice, but not neu-N/FVB mice; ref. 27).</td>
</tr>
<tr>
<td>Anti-mouse VEGF mAb</td>
<td>PVI</td>
<td>Melanoma</td>
<td>↑Immune cell infiltration.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Tumor growth delay (26).</td>
</tr>
<tr>
<td>Rgs5 knockout</td>
<td>ACT</td>
<td>Insulinoma, fibrosarcoma</td>
<td>↑Immune cell infiltration.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Survival (7).</td>
</tr>
<tr>
<td>Low-dose anti-VEGFR2 mAb</td>
<td>Mitomycin C-treated whole breast tumor cell vaccine</td>
<td>Breast carcinoma</td>
<td>↑Infiltration of CD8⁺ and CD4⁺ T cells.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑MDSCs and Tregs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Survival (8).</td>
</tr>
<tr>
<td>Adenoviral delivery of sVEGFR1/R2</td>
<td>GM-CSF–secreting whole tumor cell vaccine</td>
<td>Melanoma, colon carcinoma</td>
<td>↑The number of activated CD4⁺ and CD8⁺ T cells.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Decrease Treg.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Survival (32).</td>
</tr>
<tr>
<td>SU6668</td>
<td>Recombinant murine B7.2-IgG fusion protein and irradiated whole tumor cell vaccine</td>
<td>Breast carcinoma</td>
<td>↑Infiltration of CD8⁺ T cells.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Tumor growth delay (33).</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>Intratumoral IL-12 gene delivery by adenoviral vector plus 4-1BB activation</td>
<td>Colon carcinoma</td>
<td>↑Infiltration of CD8⁺ and CD4⁺ T cells.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑MDSC and Tregs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Survival (34).</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>Patients with renal cell carcinoma</td>
<td></td>
<td>↑MDSC and Tregs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Type 1 T-cell activity (35).</td>
</tr>
<tr>
<td>Low-dose TNF-α</td>
<td>Adoptive T-cell transfer</td>
<td>Insulinoma</td>
<td>↑Infiltration of CD8⁺ T cell.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑Survival (30).</td>
</tr>
</tbody>
</table>

NOTE: SU6668 is an inhibitor of tyrosine kinase activity of the angiogenic receptors VEGFR2, PDGFR[b], and FGFR1. Sunitinib is an inhibitor of tyrosine kinase activity of VEGFR2, PDGFR, Flt3, and c-kit.

Abbreviations: ACT, adoptive cell transfer; GM-CSF, granulocyte-macrophage colony-stimulating factor; mAb, monoclonal antibody; VEGFR2, VEGF receptor 2; PVI, the administration of anti-GP100 transgenic pmel-1 T cells plus gp100 vaccine plus IL-2 injection after 500cGy lymphodepleting whole body irradiation.
In support of this concept of dose-dependent normalization of vessels with anti-VEGF therapy, we have recently found in 2 murine breast cancer models that lower doses of anti-VEGFR2 antibody therapy (i.e., DC101, 10 or 20 mg/kg given every 3 days) induced breast tumor vascular normalization. This included a more homogeneous distribution of perfused tumor vessels, an increase in PVC coverage, and a decrease in hypoxia. In contrast, the standard antivasular DC101 treatment promoted vessel regression. In keeping with these results, lower "vascular normalizing" dose of DC101 treatment was superior to high-dose DC101 in facilitating T-cell tumor infiltration and at polarizing perivascular TAMs from an M2-like to an M1-like phenotype. In addition, low-dose DC101 treatment reduced tumor-infiltrating MDSC numbers in MCAp0008 breast tumors, compared with high-dose DC101. On the basis of these mechanisms, synchronizing vascular normalization and T-cell activation by a whole breast cancer cell vaccine significantly enhanced tumor growth inhibition in a CD8+ T-cell-dependent manner in both immunotolerant and immunogenic breast cancer models (8). This is consistent with a recent report that low-dose TNFα treatment normalized tumor vasculature and enhanced efficacy of the adoptive T-cell transfer therapy (30). Collectively, these data suggest that lower "vascular normalizing" doses of antiangiogenic therapy may be required to redirect the tumor microenvironment from immunosuppressive to immunosupportive and enhance an anticancer immunotherapy (Fig. 1).

Clinical implications and challenges

Antiangiogenic drugs have been administered in patients for nearly a decade and are often combined with chemotherapy (6, 29). However, the survival benefits of antiangiogenic drugs are in the order of a few months and treatment resistance often develops rapidly. In addition, antiangiogenic agents have failed to improve overall survival in some cancers, such as breast cancer. These issues raise questions about how antiangiogenic therapy might be more effectively used in cancer treatment. In this respect, an increasing body of evidence points to the benefit of antiangiogenic treatment when used with tumor immunotherapy.

A successful active tumor immunotherapy requires not only activated tumor antigen–specific T cells, but also the access of T cells to malignant cells and an immunosupportive environment to sustain T-cell function. These goals can be achieved by normalizing tumor vasculature, which can facilitate the delivery of T-effector cells into tumor parenchyma and alleviate the immunosuppressive tumor microenvironment (5–8, 28). Indeed, recent studies suggest that lower "vascular normalizing" dose of antiangiogenic treatment could be an effective strategy to recondition the tumor immune microenvironment for anticancer vaccine therapy (8) and potentially other immunotherapies in a clinical setting, such as the blockade of immune checkpoints (31). The ongoing clinical trial of MPDL3280A [a monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1)] in combination with a high dose (15 mg/kg) bevacizumab might shed some light on this interaction (see ClinicalTrials.gov, trial identifier NCT01633970). We propose that vascular normalizing doses of antiangiogenic treatments could improve the effectiveness of immune checkpoint inhibitors with reduced toxicity in patients.

Moreover, a number of other critical issues remain to be clarified. Tumors are highly heterogeneous. We may need to target different proangiogenic factors to induce vascular normalization in different tumors and at different times. Optimal doses of antiangiogenic agents for vascular normalization may vary by patients or by disease status and hence could be
Difficult to generalize. A reliable biomarker would be helpful to choose a "vascular normalizing" or "pruning" dose. We observed a strong correlation between an increase in tumor-infiltrating CD8+ T cells and vascular normalization. This could be a potential biomarker. Another critical issue is the schedule. Different types of immunotherapies—for example, whole tumor cell vaccine, DC vaccine, and adoptive T-cell transfer—require different times to boost anticancer immunity, thus the schedules of an antiangiogenic treatment with a tumor immunotherapy need to be optimized to achieve better anticancer efficacy. While these challenges will take some time to overcome, these concepts offer hope of developing new approaches that could enhance treatment efficacy of breast cancer and other malignancies.

**Disclosure of Potential Conflicts of Interest**

R.K. Jain has commercial research grants from Medimmune and Roche; has ownership interest (including patents) in Xitum Pharmaceuticals, SynDevRx, and Enlight Biosciences; and is a consultant/advisory board member of Noxxon Pharmaceuticals, Zyngenia, SynDevRx, XTuit Pharmaceuticals, Enlight, Hambrecht & Quist Healthcare Investors, and Hambrecht & Quist Life Sciences Investors. No potential conflicts of interest were disclosed by the other authors.

**References**


**Authors' Contributions**

**Conception and design:** Y. Huang, S. Goel, D.G. Duda, D. Fukushima, R.K. Jain

**Development of methodology:** Y. Huang

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** Y. Huang, R.K. Jain

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** Y. Huang, D.G. Duda, D. Fukushima, R.K. Jain

**Writing, review, and/or revision of the manuscript:** Y. Huang, S. Goel, D.G. Duda, D. Fukushima, R.K. Jain

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** Y. Huang, R.K. Jain

**Study supervision:** D.G. Duda, D. Fukushima, R.K. Jain

**Grant Support**

The study was supported by NIH grants P01-CA080124 (R.K. Jain, D.G. Duda, D. Fukushima); R01-CA115767, R01-CA085140, and R01-CA126642 (R.K. Jain); R21-CA139168 and R01-CA129526 (D.G. Duda); R01-C090615 (D. Fukushima); Federal Share/NCI Proton Beam Program Income Grants (R.K. Jain, D.G. Duda, D. Fukushima); Department of Defense Innovator Award W81XWH-10–1-0016 (R.K. Jain); Postdoctoral Research Fellowship W81XWH-11–1-0619 (Y. Huang); American Cancer Society Grant RSG-11–073-01-TBG (D.G. Duda); National Foundation for Cancer Research Grant (R.K. Jain); and Australian-American Fulbright Commission and an American Society of Clinical Oncology Young Investigator Award (S. Goel).

Received November 27, 2012; revised January 31, 2013; accepted February 19, 2013; published OnlineFirst February 25, 2013.


Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

Yuhui Huang, Shom Goel, Dan G. Duda, et al.


Updated version Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-4354

Cited articles This article cites 33 articles, 22 of which you can access for free at:
http://cancerres.aacrjournals.org/content/73/10/2943.full.html#ref-list-1

Citing articles This article has been cited by 26 HighWire-hosted articles. Access the articles at:
/content/73/10/2943.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.